We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
INTRODUCTION The epidermal growth factor receptor ( EGFR ) tyrosine-kinase inhibitor erlotinib is associated with survival benefits in patients with EGFR mutation-positive non-small-cell lung cancer ( NSCLC ) . This phase II , single-arm study examined the efficacy and safety of first-line erlotinib in Japanese patients with EGFR mutation-positive NSCLC . METHODS Eligible patients  received erlotinib 150 mg/day until disease progression or unacceptable toxicity . The primary endpoints were progression-free survival ( PFS ) and safety . RESULTS A high degree of concordance was observed between different mutation testing method ologies , suggesting feasibility of early , rapid detection of EGFR mutations . Median PFS was 11.8 months ( 95 % confidence interval [ CI ] : 9.7 - 15.3 ) at data cut-off ( 1 June 2012 ) ( n = 102 ) . Exon 19 deletions seemed to be associated with longer PFS compared with L858R mutations ; T790 M mutations were tentatively linked with shorter PFS . The safety profile was as expected : rash ( any grade ; 83 % ) and diarrhea ( any grade ; 81 % ) were most common . Six interstitial lung disease (ILD)-like cases were reported , and 5 were confirmed as ILD-like events by the extramural committee . Two patients died of treatment-related pneumonitis ( JAPIC Clinical Trials Information number : Japic CTI-101085 ) . CONCLUSION Erlotinib should be considered for first-line treatment in this subset of Japanese patients , with close monitoring for ILD-like events
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV